Box 1. Activation and regulation of the complement system

Complement activation by mAbs can cause direct tumor cell lysis or enhance antibody-dependent cell-mediated cytotoxicity. However, tumor cells are protected from complement-mediated injury by membrane-bound complement regulatory proteins (mCRP) that are often expressed at elevated levels on tumor ce...

Full description

Saved in:
Bibliographic Details
Published in:Trends in immunology 2004-03, Vol.25 (3), p.158
Main Authors: Gelderman, Kyra A, Tomlinson, Stephen, Ross, Gordon D, Gorter, Arko
Format: Article
Language:English
Subjects:
Binding sites
Breast cancer
Cancer therapies
Clinical trials
Colorectal cancer
Cytotoxicity
Hematology
Immunotherapy
Leukemia
Lung cancer
Lymphoma
Microorganisms
Tumors
Yeast
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 3
container_start_page 158
container_title Trends in immunology
container_volume 25
creator Gelderman, Kyra A
Tomlinson, Stephen
Ross, Gordon D
Gorter, Arko
description Complement activation by mAbs can cause direct tumor cell lysis or enhance antibody-dependent cell-mediated cytotoxicity. However, tumor cells are protected from complement-mediated injury by membrane-bound complement regulatory proteins (mCRP) that are often expressed at elevated levels on tumor cells. Recent studies indicate that blocking or overwhelming the function of tumor cell mCRP might substantially improve the efficacy of monoclonal antibody (mAb) immunotherapy. In addition, the use of β-glucan as an adjuvant for mAb immunotherapy enables iC3b deposited on tumor cells by mAbs to activate complement receptor 3 (CR3) on effector cells, thus inducing CR3-dependent cellular cytotoxicity. These strategies provide novel cell-mediated mechanisms of tumor cytotoxicity that are additive to all other mAb effector mechanisms.
doi_str_mv 10.1016/j.it.2004.01.008
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1506926965</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3245265991</sourcerecordid><originalsourceid>FETCH-proquest_journals_15069269653</originalsourceid><addsrcrecordid>eNqNir0OgjAURhujifizOzZxpt6L0NJRjcYHcCcEi0JKi7QYfXtNNM5O3zk5HyELBIaAfFWzyrMIIGaADCAdkABjgWEsUxz-GPiYTJyrATARQgREbu2DIqObwlf33FfW0Nycaacuvf6oLam_KlrYptWqUcZT93ReNTMyKnPt1Py7U7I87E-7Y9h29tYr57Pa9p15pwwT4DLikifr_14vYks8wA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1506926965</pqid></control><display><type>article</type><title>Box 1. Activation and regulation of the complement system</title><source>Elsevier</source><creator>Gelderman, Kyra A ; Tomlinson, Stephen ; Ross, Gordon D ; Gorter, Arko</creator><creatorcontrib>Gelderman, Kyra A ; Tomlinson, Stephen ; Ross, Gordon D ; Gorter, Arko</creatorcontrib><description>Complement activation by mAbs can cause direct tumor cell lysis or enhance antibody-dependent cell-mediated cytotoxicity. However, tumor cells are protected from complement-mediated injury by membrane-bound complement regulatory proteins (mCRP) that are often expressed at elevated levels on tumor cells. Recent studies indicate that blocking or overwhelming the function of tumor cell mCRP might substantially improve the efficacy of monoclonal antibody (mAb) immunotherapy. In addition, the use of β-glucan as an adjuvant for mAb immunotherapy enables iC3b deposited on tumor cells by mAbs to activate complement receptor 3 (CR3) on effector cells, thus inducing CR3-dependent cellular cytotoxicity. These strategies provide novel cell-mediated mechanisms of tumor cytotoxicity that are additive to all other mAb effector mechanisms.</description><identifier>ISSN: 1471-4906</identifier><identifier>EISSN: 1471-4981</identifier><identifier>DOI: 10.1016/j.it.2004.01.008</identifier><language>eng</language><publisher>Oxford: Elsevier Limited</publisher><subject>Binding sites ; Breast cancer ; Cancer therapies ; Clinical trials ; Colorectal cancer ; Cytotoxicity ; Hematology ; Immunotherapy ; Leukemia ; Lung cancer ; Lymphoma ; Microorganisms ; Tumors ; Yeast</subject><ispartof>Trends in immunology, 2004-03, Vol.25 (3), p.158</ispartof><rights>Copyright Elsevier Limited Mar 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Gelderman, Kyra A</creatorcontrib><creatorcontrib>Tomlinson, Stephen</creatorcontrib><creatorcontrib>Ross, Gordon D</creatorcontrib><creatorcontrib>Gorter, Arko</creatorcontrib><title>Box 1. Activation and regulation of the complement system</title><title>Trends in immunology</title><description>Complement activation by mAbs can cause direct tumor cell lysis or enhance antibody-dependent cell-mediated cytotoxicity. However, tumor cells are protected from complement-mediated injury by membrane-bound complement regulatory proteins (mCRP) that are often expressed at elevated levels on tumor cells. Recent studies indicate that blocking or overwhelming the function of tumor cell mCRP might substantially improve the efficacy of monoclonal antibody (mAb) immunotherapy. In addition, the use of β-glucan as an adjuvant for mAb immunotherapy enables iC3b deposited on tumor cells by mAbs to activate complement receptor 3 (CR3) on effector cells, thus inducing CR3-dependent cellular cytotoxicity. These strategies provide novel cell-mediated mechanisms of tumor cytotoxicity that are additive to all other mAb effector mechanisms.</description><subject>Binding sites</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Clinical trials</subject><subject>Colorectal cancer</subject><subject>Cytotoxicity</subject><subject>Hematology</subject><subject>Immunotherapy</subject><subject>Leukemia</subject><subject>Lung cancer</subject><subject>Lymphoma</subject><subject>Microorganisms</subject><subject>Tumors</subject><subject>Yeast</subject><issn>1471-4906</issn><issn>1471-4981</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNqNir0OgjAURhujifizOzZxpt6L0NJRjcYHcCcEi0JKi7QYfXtNNM5O3zk5HyELBIaAfFWzyrMIIGaADCAdkABjgWEsUxz-GPiYTJyrATARQgREbu2DIqObwlf33FfW0Nycaacuvf6oLam_KlrYptWqUcZT93ReNTMyKnPt1Py7U7I87E-7Y9h29tYr57Pa9p15pwwT4DLikifr_14vYks8wA</recordid><startdate>20040301</startdate><enddate>20040301</enddate><creator>Gelderman, Kyra A</creator><creator>Tomlinson, Stephen</creator><creator>Ross, Gordon D</creator><creator>Gorter, Arko</creator><general>Elsevier Limited</general><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope></search><sort><creationdate>20040301</creationdate><title>Box 1. Activation and regulation of the complement system</title><author>Gelderman, Kyra A ; Tomlinson, Stephen ; Ross, Gordon D ; Gorter, Arko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_15069269653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Binding sites</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Clinical trials</topic><topic>Colorectal cancer</topic><topic>Cytotoxicity</topic><topic>Hematology</topic><topic>Immunotherapy</topic><topic>Leukemia</topic><topic>Lung cancer</topic><topic>Lymphoma</topic><topic>Microorganisms</topic><topic>Tumors</topic><topic>Yeast</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gelderman, Kyra A</creatorcontrib><creatorcontrib>Tomlinson, Stephen</creatorcontrib><creatorcontrib>Ross, Gordon D</creatorcontrib><creatorcontrib>Gorter, Arko</creatorcontrib><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>Trends in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gelderman, Kyra A</au><au>Tomlinson, Stephen</au><au>Ross, Gordon D</au><au>Gorter, Arko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Box 1. Activation and regulation of the complement system</atitle><jtitle>Trends in immunology</jtitle><date>2004-03-01</date><risdate>2004</risdate><volume>25</volume><issue>3</issue><spage>158</spage><pages>158-</pages><issn>1471-4906</issn><eissn>1471-4981</eissn><abstract>Complement activation by mAbs can cause direct tumor cell lysis or enhance antibody-dependent cell-mediated cytotoxicity. However, tumor cells are protected from complement-mediated injury by membrane-bound complement regulatory proteins (mCRP) that are often expressed at elevated levels on tumor cells. Recent studies indicate that blocking or overwhelming the function of tumor cell mCRP might substantially improve the efficacy of monoclonal antibody (mAb) immunotherapy. In addition, the use of β-glucan as an adjuvant for mAb immunotherapy enables iC3b deposited on tumor cells by mAbs to activate complement receptor 3 (CR3) on effector cells, thus inducing CR3-dependent cellular cytotoxicity. These strategies provide novel cell-mediated mechanisms of tumor cytotoxicity that are additive to all other mAb effector mechanisms.</abstract><cop>Oxford</cop><pub>Elsevier Limited</pub><doi>10.1016/j.it.2004.01.008</doi></addata></record>
fulltext fulltext
identifier ISSN: 1471-4906
ispartof Trends in immunology, 2004-03, Vol.25 (3), p.158
issn 1471-4906
1471-4981
language eng
recordid cdi_proquest_journals_1506926965
source Elsevier
subjects Binding sites
Breast cancer
Cancer therapies
Clinical trials
Colorectal cancer
Cytotoxicity
Hematology
Immunotherapy
Leukemia
Lung cancer
Lymphoma
Microorganisms
Tumors
Yeast
title Box 1. Activation and regulation of the complement system
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T10%3A12%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Box%201.%20Activation%20and%20regulation%20of%20the%20complement%20system&rft.jtitle=Trends%20in%20immunology&rft.au=Gelderman,%20Kyra%20A&rft.date=2004-03-01&rft.volume=25&rft.issue=3&rft.spage=158&rft.pages=158-&rft.issn=1471-4906&rft.eissn=1471-4981&rft_id=info:doi/10.1016/j.it.2004.01.008&rft_dat=%3Cproquest%3E3245265991%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_15069269653%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1506926965&rft_id=info:pmid/&rfr_iscdi=true